Body weight does not predict for anti-Xa levels after fixed dose prophylaxis with enoxaparin after orthopedic surgery

Thrombosis Research

Volumn 91, Issue 3, 1998, Pages 137-142

  Kovacs, M J ^a,b   Weir, K ^b   MacKinnon, K ^b   Keeney, M ^b   Brien, W F ^a,c   Cruickshank, M K ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

^c ST JOSEPH S HEALTH CENTRE   (Canada)

Author keywords

Anti Xa levels; Low molecular weight heparin; Outcome; Venous thromboembolism

Indexed keywords

BLOOD CLOTTING FACTOR 10A; ENOXAPARIN;

ADULT; AGED; ARTICLE; BODY WEIGHT; DIAGNOSTIC VALUE; HUMAN; MAJOR CLINICAL STUDY; ORTHOPEDIC SURGERY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOSIS;

AGED; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; BODY WEIGHT; ENOXAPARIN; FACTOR XA; FEMALE; HUMANS; MALE; POSTOPERATIVE COMPLICATIONS; THROMBOSIS;

EID: 0032144285     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(98)00083-8     Document Type: Article

References (20)

1. Turpie AGG, Levine MN, Hirsh J, Carter CJ, Jay RM, Powers PJ, Andrew M, Hull RD, Gent M. A randomized controlled trial of a low-molecular weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. New Engl J Med 1986;315:925-9.
2. Leclerc JR, Geerts WH, Desjardins L, Jobin F, Laroche F, Delorme F, Haviernick S, Atkinson S, Borgouin J. Prevention of deep vein thrombosis after major knee surgery - a randomized, double-blind trial comparing a low molecular weight heparin fragment (Enoxaparin) to placebo. Thromb Haemost 1992; 67:417-23.
3. Lassen MR, Borris LC, Christiansen HM, Boll KL, Eiskjaer SP, Nielsen BW, Schott P, Olsen AD. Prevention of thromboembolism in 190 hip arthroplasties. Acta Orthop Scand 1991; 62:33-8.
4. Green D, Hirsh J, Heit J, Prins M, Davidson B, Lensing AWA. Low molecular weight heparin: a critical analysis of clinical trials. Pharmacol Rev 1994;46:89-109.
5. Leyvraz PF, Bachmann F, Hoek J, Büller HR, Postel M, Samama M, Vandenbroek MD. Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin. Br Med J 1991;303:543-8.
6. Spiro TE, Johnson GJ, Christie MJ, Lyons RM, MacFarlane DE, Blasier RB, Tremaine MD, Enoxaparin Clinical Trial Group. Efficacy and safety of enoxaparin to prevent deep venous thrombosis after hip replacement surgery. Ann Intern Med 1994;121:81-9.
7. Matzch T, Bergqvist D, Fredin H, Hedner U. Low molecular weight heparin compared with dextran as prophylaxis against thrombosis after total hip replacement. Acta Chir Scand 1990; 156:445-50.
8. Powers PJ, Gent M, Jay RM, Julian DH, Turpie AGG, Levine M, Hirsh J. A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fracture hip. Arch Intern Med 1989;149:771-4.
9. Samama M, Bernard P, Bonnardot JP, Combe-Tamzali S, Lanson Y, Tissot E, on behalf of the participants of the Groupe d'Etude de l'Enoxaparine (GENOX) multicentre trial. Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis. Br J Surg 1988;75:128-31.
10. Francis CW, Pellegrini VD, Marder VJ, Totterman S, Harris CM, Gabriel R, Azodo MV, Leibert KM. Comparison of warfarin and external pneumatic compression in prevention of venous thrombosis after total hip replacement: JAMA 1992;267:2911-5.
11. Boneu B. Low-molecular weight heparin therapy: Is monitoring needed? Thromb Haemost 1994;72:330-4.
12. Walenga JM. Practical issues on the laboratory monitoring of low molecular weight heparins and related polysaccharides. Semin Thromb Hemost 1993;19:69-72.
13. Ozawa T, Mammen EF. LMW Heparin (Anti-Xa) assays for clinical monitoring and pharmacokinetic studies on the automated coagulation laboratory (ACL). Thromb Res 1992;66:287-98.
14. Levine MN, Planes A, Hirsh J, Goodyear M, Vochelle N, Gent M. The relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparin low molecular weight heparin to prevent deep vein thrombosis after hip replacement. Thromb Haemost 1989;62:940-4.
15. R (LMWH) or unfractionated heparin. Thromb Res 1992;65:641-50.
16. Bacher P, Horst B, Breyer HG, Hoppensteadt DA, Walenga JM, Fareed J. Postoperative monitoring of low molecular weight heparin prophylaxis in high-risk patients. Semin Thromb Hemost 1993;19:73-8.
17. Kessler CM, Esparraguera IM, Jacobs HM, Druy E, Fortune WP. Holloway DS, Giordano J, Davidson BL. Monitoring the anticoagulant effects of a low molecular weight heparin preparation: Correlation of assays in orthopedic surgery patients receiving ardeparin sodium for prophylaxis of deep venous thrombosis. Am J Clin Pathol 1995;103:642-8.
18. Weitz JI. Low-molecular-weight heparins. New Engl J Med 1997;337:688-98.
19. Leclerc JR, Gent M, Hirsh J, Geerts W, Ginsberg J, Members of the Canadian Collaborative Group. The incidence of symptomatic venous thromboembolism during and after prophylaxis with Enoxaparin: A multi-institutional cohort study in patients who underwent hip or knee arthroplasty. Arch Intern Med 1998;158:873-878.
20. Robinson KS, Anderson DR, Gross M, Petrie D, Leighton R, Stanish W, Alexander D, Mitchell M, Flemming B, Gent M. Ultrasonographic screening before hospital discharge for deep venous thrombosis after arthroplasty: The post-arthroplasty screening study. Ann Intern Med 1997;127:439-45.